In a report released today, David Grossman from Stifel Nicolaus maintained a Hold rating on Health Catalyst (HCAT – Research Report), with a price target of $10.00. The company’s shares closed yesterday at $9.94.
According to TipRanks, Grossman is a 5-star analyst with an average return of 10.9% and a 62.79% success rate. Grossman covers the Technology sector, focusing on stocks such as Infosys, Accenture, and International Business Machines.
Currently, the analyst consensus on Health Catalyst is a Strong Buy with an average price target of $12.67.
See today’s best-performing stocks on TipRanks >>
The company has a one-year high of $15.87 and a one-year low of $6.60. Currently, Health Catalyst has an average volume of 563K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Health Catalyst (HCAT) Company Description:
Health Catalyst, Inc. engages in the provision of data and analytics technology and services to healthcare organizations. It operates through the Technology, and Professional Services segments. The Technology segment includes its data platform, analytics applications, and support services. The Professional Services segment combines analytics, implementation, strategic advisory, outsource, and improvement services to deliver expertise to its customers. The company was founded by Steven C. Barlow and Thomas D. Burton in 2008 and is headquartered in Salt Lake City, UT.
Read More on HCAT:
- Tesla downgraded, Coinbase upgraded: Wall Street’s top analyst calls
- Health Catalyst upgraded to Buy from Neutral at Guggenheim
- Health Catalyst price target raised to $17 from $12 at Piper Sandler
- ‘Profitability Is the Key’: Barclays Says These 3 Health Tech Stocks Are Poised for Growth
- Health Catalyst upgraded to Outperform at Evercore ISI on IT demand inflection
